# Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT03430700** · PHASE2 · UNKNOWN · sponsor: **University College, London** · enrollment: 28 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03430700
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-16
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430700, "Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03430700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*